EXPO has been the subject of several other research reports. Zacks Investment Research raised Focus Financial Partners from a hold rating to a buy rating and set a $31.00 target price for the company in a research note on Monday, June 24th. Cantor Fitzgerald reaffirmed a buy rating on shares of Tivity Health in a report on Monday, April 22nd. Finally, William Blair reaffirmed a market perform rating on shares of W W Grainger in a report on Monday, April 22nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $61.33.
Shares of EXPO opened at $60.15 on Tuesday. The firm has a 50 day simple moving average of $57.98. Exponent has a 52-week low of $44.44 and a 52-week high of $60.38. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of 42.87 and a beta of 0.44. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.22 and a current ratio of 4.22.
The business also recently announced a quarterly dividend, which was paid on Friday, June 21st. Stockholders of record on Friday, June 7th were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 1.06%. The ex-dividend date was Thursday, June 6th. Exponent’s dividend payout ratio is 51.20%.
In other news, Director Carol Lindstrom sold 1,800 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $56.92, for a total transaction of $102,456.00. Following the completion of the sale, the director now directly owns 3,212 shares of the company’s stock, valued at $182,827.04. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.30% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in Exponent by 0.3% in the 1st quarter. BlackRock Inc. now owns 7,524,004 shares of the business services provider’s stock worth $434,286,000 after acquiring an additional 21,968 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in Exponent by 0.4% in the 1st quarter. Conestoga Capital Advisors LLC now owns 2,319,167 shares of the business services provider’s stock worth $133,862,000 after acquiring an additional 8,446 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Exponent by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 1,036,313 shares of the business services provider’s stock worth $59,816,000 after acquiring an additional 14,524 shares in the last quarter. FMR LLC lifted its stake in Exponent by 39.8% in the 1st quarter. FMR LLC now owns 993,288 shares of the business services provider’s stock worth $57,333,000 after acquiring an additional 282,530 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Exponent by 9.6% in the 4th quarter. Geode Capital Management LLC now owns 648,674 shares of the business services provider’s stock worth $32,893,000 after acquiring an additional 56,600 shares in the last quarter. 88.80% of the stock is owned by hedge funds and other institutional investors.
Exponent Company Profile
Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation.
Read More: What is the Rule of 72?
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.